Elekta will publish its full-year report for 2011/12 on June 5, 2012 with the following schedule:
· The report will be published at 07:30 CET.
· Elekta will host a telephone conference at 10:00-11:00 CET, with Tomas Puusepp, President and CEO and Håkan Bergström, CFO.
To take part in the conference call, please dial in about 5-10 minutes in advance and use the access code 917247.
· Swedish dial-in number: +46 (0)8 5052 0110
· UK dial-in number: +44 (0)20 7162 0077
· US dial-in number: + 1 334 323 6201
The telephone conference will also be broadcast live online (audio only). Please use this link: http://webeventservices.reg.meeting-stream.com/64156_elekta
Elekta’s Capital Markets Day – June 19, 2012 in Stockholm
Elekta invites equity analysts, investors and media representatives to a Capital Markets Day in Stockholm, June 19. Tomas Puusepp, President and CEO, and other members of Elekta’s management team will give presentations focusing on Elekta’s strategy and development. Lunch will be served from 12:15 CET and the presentations will start at 13:00 and end at approximately 15:30. The venue is Grand Hotel, Stockholm, Sweden.
To attend this Capital Markets Day, please register by e-mail to email@example.com no later than June 5, 2012.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.